|
US3227725A
(en)
|
1962-04-17 |
1966-01-04 |
Union Carbide Corp |
Certain 3,5-disubstituted 1,2,4-oxadiazole compounds
|
|
US4172896A
(en)
|
1978-06-05 |
1979-10-30 |
Dainippon Pharmaceutical Co., Ltd. |
Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
|
|
TW201311B
(enExample)
|
1991-06-17 |
1993-03-01 |
Hoffmann La Roche |
|
|
GB9217295D0
(en)
|
1992-08-14 |
1992-09-30 |
Wellcome Found |
Controlled released tablets
|
|
US5541231A
(en)
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
|
GB9315856D0
(en)
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
|
US5358970A
(en)
|
1993-08-12 |
1994-10-25 |
Burroughs Wellcome Co. |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
|
CA2143246C
(en)
|
1994-03-16 |
2000-08-22 |
Thierry Godel |
Imidazodiazepines
|
|
ATE391492T1
(de)
|
1997-07-29 |
2008-04-15 |
Alcon Lab Inc |
Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat
|
|
EP1051167A1
(en)
|
1998-01-29 |
2000-11-15 |
Sepracor, Inc. |
Pharmaceutical uses of optically pure (-) -bupropion
|
|
WO2001014557A1
(en)
|
1999-08-23 |
2001-03-01 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
|
US8889112B2
(en)
|
1999-09-16 |
2014-11-18 |
Ocularis Pharma, Llc |
Ophthalmic formulations including selective alpha 1 antagonists
|
|
JP2004533226A
(ja)
|
2001-04-02 |
2004-11-04 |
ワイス |
Ｂ７−４に対するｐｄ−１、ａレセプター、およびその使用
|
|
AU2002258941A1
(en)
|
2001-04-20 |
2002-11-05 |
Mayo Foundation For Medical Education And Research |
Methods of enhancing cell responsiveness
|
|
CA2466279A1
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
GB0204159D0
(en)
|
2002-02-22 |
2002-04-10 |
British Biotech Pharm |
Metalloproteinase inhibitors
|
|
EP2206517B1
(en)
|
2002-07-03 |
2023-08-02 |
Ono Pharmaceutical Co., Ltd. |
Immunopotentiating compositions comprising anti-PD-L1 antibodies
|
|
CN1753912B
(zh)
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US6933289B2
(en)
|
2003-07-01 |
2005-08-23 |
Allergan, Inc. |
Inhibition of irritating side effects associated with use of a topical ophthalmic medication
|
|
ES2593113T3
(es)
|
2003-08-07 |
2016-12-05 |
Allergan, Inc. |
Composiciones para el suministro de agentes terapéuticos en los ojos y métodos para obtener y usar los mismos
|
|
US20050059744A1
(en)
|
2003-09-12 |
2005-03-17 |
Allergan, Inc. |
Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
|
|
TW200524601A
(en)
|
2003-12-05 |
2005-08-01 |
Bristol Myers Squibb Co |
Heterocyclic anti-migraine agents
|
|
US7585881B2
(en)
|
2004-02-18 |
2009-09-08 |
Astrazeneca Ab |
Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
EP1593671A1
(en)
|
2004-03-05 |
2005-11-09 |
Graffinity Pharmaceuticals AG |
DPP-IV inhibitors
|
|
WO2006067532A1
(en)
|
2004-12-24 |
2006-06-29 |
Prosidion Ltd |
G-protein coupled receptor agonists
|
|
ES2720160T3
(es)
|
2005-05-09 |
2019-07-18 |
Ono Pharmaceutical Co |
Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
|
|
JP2008546643A
(ja)
|
2005-06-06 |
2008-12-25 |
スミスクライン ビーチャム コーポレーション |
４−置換アリールアミン誘導体および医薬組成物におけるその使用
|
|
AU2006331731A1
(en)
|
2005-12-20 |
2007-07-05 |
Merck Sharp & Dohme Corp. |
Niacin receptor agonists, compositions containing such compounds and methods of treatment
|
|
US8748627B2
(en)
|
2006-02-15 |
2014-06-10 |
Abbvie Inc. |
Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
|
|
WO2008011557A2
(en)
|
2006-07-20 |
2008-01-24 |
Borchardt Allen J |
Heteroaryl inhibitors of rho kinase
|
|
CL2007002743A1
(es)
|
2006-09-25 |
2008-07-11 |
Pct Therapeutics Inc Soc Organ |
Forma cristalina del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico; composicion farmaceutica que comprende a dicha forma cristalina; y su uso para modular la terminacion prematura de traslado o decaimiento de marn, tales como carcicoma.
|
|
JP5191537B2
(ja)
|
2007-06-18 |
2013-05-08 |
エム・エス・ディー・オス・ベー・フェー |
ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
|
|
WO2009006555A2
(en)
|
2007-07-02 |
2009-01-08 |
Yu, Ming |
Methods, composition, targets for combinational cancer treatments
|
|
US7868001B2
(en)
|
2007-11-02 |
2011-01-11 |
Hutchison Medipharma Enterprises Limited |
Cytokine inhibitors
|
|
BRPI0908849A2
(pt)
|
2008-02-22 |
2015-08-25 |
Irm Llc |
Composto e composições como c-kit e inibidores de pdgfr quinase
|
|
WO2010033701A2
(en)
|
2008-09-19 |
2010-03-25 |
Genzyme Corporation |
Inhibitors of sphingosine kinase 1
|
|
EP2349266A4
(en)
|
2008-10-30 |
2012-06-06 |
Elixir Pharmaceuticals Inc |
Sulphonamide-containing compounds and their uses
|
|
HUE065752T2
(hu)
|
2008-12-09 |
2024-06-28 |
Hoffmann La Roche |
Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
|
|
PT2504364T
(pt)
|
2009-11-24 |
2017-11-14 |
Medimmune Ltd |
Agentes de ligação direcionados contra b7-h1
|
|
US20130022629A1
(en)
|
2010-01-04 |
2013-01-24 |
Sharpe Arlene H |
Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
|
|
WO2011137587A1
(en)
|
2010-05-06 |
2011-11-10 |
Hutchison Medipharma Limited |
Cytokine inhibitors
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
WO2012129564A2
(en)
|
2011-03-24 |
2012-09-27 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Proteasome chymotrypsin-like inhibition using pi-1833 analogs
|
|
CN103732238A
(zh)
|
2011-06-08 |
2014-04-16 |
奥瑞基尼探索技术有限公司 |
用于免疫调节的治疗性化合物
|
|
EP2771337B1
(en)
|
2011-09-27 |
2017-08-02 |
Novartis AG |
3-(pyrimidin-4-yl)-oxazolidin-2-ones as inhibitors of mutant idh
|
|
CN104159911A
(zh)
|
2012-03-07 |
2014-11-19 |
奥瑞基尼探索技术有限公司 |
作为免疫调节剂的模拟肽化合物
|
|
CN104245726A
(zh)
|
2012-03-29 |
2014-12-24 |
奥瑞基尼探索技术有限公司 |
来自人pd1的bc环的免疫调节环状化合物
|
|
CA2886433C
(en)
|
2012-10-04 |
2022-01-04 |
Dana-Farber Cancer Institute, Inc. |
Human monoclonal anti-pd-l1 antibodies and methods of use
|
|
AU2013329186B2
(en)
|
2012-10-10 |
2019-02-14 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
JP5941598B2
(ja)
|
2013-01-09 |
2016-06-29 |
ギリアード サイエンシーズ， インコーポレイテッド |
５員ヘテロアリールおよびそれらの抗ウイルス剤としての使用
|
|
WO2014141104A1
(en)
|
2013-03-14 |
2014-09-18 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
|
WO2014147586A1
(en)
|
2013-03-22 |
2014-09-25 |
Novartis Ag |
1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
|
|
AU2014290069B2
(en)
|
2013-07-16 |
2019-01-03 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
|
|
HRP20181251T1
(hr)
|
2013-09-06 |
2018-10-05 |
Aurigene Discovery Technologies Limited |
Derivati 1,3,4-oksadiazola i 1,3,4-tiadiazola kao imunomodulatori
|
|
CU24362B1
(es)
|
2013-09-06 |
2018-10-04 |
Aurigene Discovery Tech Ltd |
Derivados de 1,2,4-oxadiazol como inmunomoduladores
|
|
JP6623353B2
(ja)
|
2013-09-13 |
2019-12-25 |
ベイジーン スウィッツァーランド ゲーエムベーハー |
抗ｐｄ−１抗体並びにその治療及び診断のための使用
|
|
GB2516515B8
(en)
|
2013-12-04 |
2016-10-05 |
Intelligent Growth Solutions Ltd |
Automated arrangement to grow plants under lighting in a vertical tower
|
|
US10174012B2
(en)
|
2014-11-04 |
2019-01-08 |
The University Of Kansas |
LKB1-AMPK activators for therapeutic use in polycystic kidney disease
|
|
MX384444B
(es)
|
2015-03-10 |
2025-03-14 |
Aurigene Discovery Tech Ltd |
Compuestos de 1,2,4-oxadiazol y tiadiazol como inmunomoduladores
|
|
CA2979145A1
(en)
|
2015-03-10 |
2016-09-15 |
Aurigene Discovery Technologies Limited |
1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
|
|
WO2016142886A2
(en)
|
2015-03-10 |
2016-09-15 |
Aurigene Discovery Technologies Limited |
3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
|
GB201517217D0
(en)
*
|
2015-09-29 |
2015-11-11 |
Astex Therapeutics Ltd And Cancer Res Technology Ltd |
Pharmaceutical compounds
|
|
SMT202200118T1
(it)
|
2015-11-03 |
2022-05-12 |
Janssen Biotech Inc |
Anticorpi che legano specificamente pd-1 e loro usi
|
|
WO2018047143A1
(en)
|
2016-09-12 |
2018-03-15 |
Aurigene Discovery Technologies Limited |
Vista signaling pathway inhibitory compounds useful as immunomodulators
|
|
WO2018051254A1
(en)
|
2016-09-14 |
2018-03-22 |
Aurigene Discovery Technologies Limited |
Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
|
|
MX2019004561A
(es)
|
2016-10-20 |
2019-08-05 |
Aurigene Discovery Tech Ltd |
Inhibidores dobles del supresor de inmunoglobulina del dominio v de la activacion de linfocitos t (vista) y las vias de muerte programada 1 (pd-1).
|
|
WO2019061324A1
(en)
|
2017-09-29 |
2019-04-04 |
Curis Inc. |
CRYSTALLINE FORMS OF IMMUNOMODULATORS
|
|
BR112020006669A2
(pt)
|
2017-10-11 |
2020-09-24 |
Aurigene Discovery Technologies Limited |
formas cristalinas de 1,2,4-oxadiazol 3-substituído
|
|
KR20200083503A
(ko)
|
2017-11-03 |
2020-07-08 |
오리진 디스커버리 테크놀로지스 리미티드 |
Tim-3 경로와 pd-1 경로의 이중 저해제
|
|
EA202090749A1
(ru)
|
2017-11-06 |
2020-08-19 |
Ориджен Дискавери Текнолоджис Лимитед |
Способы совместной терапии для иммуномодуляции
|